Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC).

被引：0
作者：
Ramos, M
Casal, J
Galán, A
Almanza, C
León, L
Amenedo, M
Gonzalez, A
Huidobro, G
Giner, V
机构：
[1] Ctr Oncol Galicia, La Coruna, Spain
[2] Hosp Meixoeiro, Vigo, Spain
[3] Hosp Sagunto, Valencia, Spain
[4] Clin Povisa, Vigo, Spain
[5] Hosp Clin Santiago, Santiago De Compostela, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：54S / 54S
页数：1
相关论文
共 50 条
  • [11] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [12] Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
    S. H. Waters
    A. Gillibrand
    H. Berry
    S. Kumar
    G. Velikova
    D. J. Dodwell
    Timothy J. Perren
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 407 - 412
  • [13] Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
    Waters, S. H.
    Gillibrand, A.
    Berry, H.
    Kumar, S.
    Velikova, G.
    Dodwell, D. J.
    Perren, Timothy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 407 - 412
  • [14] Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer
    Khayat, D
    Chollet, P
    Antoine, EC
    Monfardini, S
    Ambrosini, G
    Benhammouda, A
    Mazen, MF
    Sorio, R
    Borg-Olivier, O
    Ramazeilles, C
    Azli, N
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3367 - 3375
  • [15] Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer.
    Lorenzo, A.
    Modolell, A.
    Valero, P.
    Murillo, L.
    Garcia-Bueno, J. M.
    Yubero, A.
    Machengs, I. H.
    CANCER RESEARCH, 2009, 69 (02) : 202S - 202S
  • [16] Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
    Mavroudis, D
    Alexopoulos, A
    Ziras, N
    Malamos, N
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Tsavaris, N
    Potamianou, A
    Rigatos, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 (10) : 1249 - 1254
  • [17] A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study
    Vici, P.
    Giotta, F.
    Di Lauro, L.
    Sergi, D.
    Vizza, E.
    Mariani, L.
    Latorre, A.
    Pizzuti, L.
    D'Amico, C.
    Giannarelli, D.
    Colucci, G.
    ONCOLOGY, 2011, 81 (3-4) : 230 - 236
  • [18] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [19] Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer:: Results of a multicenter phase II study
    Palmeri, S
    Vaglica, M
    Spada, S
    Filippelli, G
    Farris, A
    Palmeri, L
    Massidda, B
    Misino, A
    Ferraù, F
    Comella, G
    Leonardi, V
    Condemi, G
    Mangiameli, A
    De Cataldis, G
    Macaluso, MC
    Cajozzoo, M
    Iannitto, E
    Danova, M
    ONCOLOGY, 2005, 68 (4-6) : 438 - 445
  • [20] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    Venturini, M
    Bighin, C
    Monfardini, S
    Cappuzzo, F
    Olmeo, N
    Durando, A
    Puglisi, F
    Nicoletto, O
    Lambiase, A
    Del Mastro, L
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (01) : 45 - 53
12345